Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 3
2005 4
2006 8
2007 5
2008 9
2009 7
2010 6
2011 6
2012 6
2013 7
2014 4
2015 3
2016 10
2017 14
2018 9
2019 10
2020 16
2021 12
2022 15
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy.
Lischalk JW, Sanchez A, Santos VF, Mendez C, Akerman M, Carpenter T, Tam M, Byun D, Wise DR, Mahadevan A, Evans A, Huang W, Katz A, Lepor H, Haas JA. Lischalk JW, et al. Among authors: katz a. Radiat Oncol. 2024 Mar 4;19(1):29. doi: 10.1186/s13014-023-02397-z. Radiat Oncol. 2024. PMID: 38439040 Free PMC article.
Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands.
Hurwitz JC, Haas J, Mendez C, Sanchez A, Santos VF, Akerman M, Carpenter T, Tam M, Katz A, Corcoran A, Mahadevan A, Taneja SS, Lepor H, Lischalk JW. Hurwitz JC, et al. Among authors: katz a. Pract Radiat Oncol. 2023 Nov 19:S1879-8500(23)00302-8. doi: 10.1016/j.prro.2023.11.008. Online ahead of print. Pract Radiat Oncol. 2023. PMID: 37984713
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ; Focal Therapy Society. Deivasigamani S, et al. Among authors: katz ae. Eur Urol. 2023 Dec;84(6):547-560. doi: 10.1016/j.eururo.2023.06.013. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37419773 Review.
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Chamie K, Chang SS, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Katz AE, Koo AS, Sexton WJ, Tikhonenkov SN, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Taha SA, Sender L, Reddy S, Soon-Shiong P. Chamie K, et al. Among authors: katz ae. NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10. NEJM Evid. 2023. PMID: 38320011
148 results